OLVIG
CRDL

Oliver Lagore Vanvalin Investment Group’s Cardiol Therapeutics CRDL Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$445 – 852
2023
Q2 		$445 Hold
500
– – ﹤0.01% 723
2023
Q1 		$244 Hold
500
– – ﹤0.01% 673
2022
Q4 		$255 Hold
500
– – ﹤0.01% 634
2022
Q3 		$1K Hold
500
– – ﹤0.01% 563
2022
Q2 		$1K Hold
500
– – ﹤0.01% 538
2022
Q1 		$1K Buy
+500
New +$825 ﹤0.01% 528

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
AI
AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's CRDL Position: Q3 2023 in Review

Oliver Lagore Vanvalin Investment Group sold out of Cardiol Therapeutics (CRDL) in Q3 2023, closing a stake of 500 shares — an estimated $445 sold.

Oliver Lagore Vanvalin Investment Group first reported a position in CRDL in Q1 2022 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 35 funds tracked by Wall St. Rank hold CRDL as of Q3 2023.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Cardiol Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 500 Cardiol Therapeutics shares in Q3 2023, an estimated $445.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 6 quarters.
  • Oliver Lagore Vanvalin Investment Group's Cardiol Therapeutics position peaked at $1K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2023.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q3 2023, filed 9 Nov 2023.